Day: October 8, 2021

RUTHERFORD, N.J., Oct. 08, 2021 (GLOBE NEWSWIRE) — Blue Foundry Bancorp (NASDAQ: BLFY) (the “Company”), the holding company for Blue Foundry Bank, announced that it will release financial results for the quarter ended September 30, 2021 on the morning of Friday, October 22, 2021. A copy of the earnings release will be available on the Company’s website, https://ir.bluefoundrybank.com/, in the News section and at the SEC’s website, www.sec.gov. Representatives of the Company will hold a conference call for investors on Friday, October 22, 2021 at 11:00AM (EST) to discuss the Third Quarter 2021 earnings. The conference call will be recorded and will be available on the Company’s website for one month. We encourage participants to pre-register for the webcast by using the link below to listen to the call. Upon registration, participants...

Confirmed Objective Response Rate of 48 Percent in Patients with NTRK+ TKI-Pretreated Advanced Solid Tumors Confirmed Objective Response Rate of 62 Percent in NTRK+ TKI-Pretreated Advanced Solid Tumor Patients with Solvent Front Mutations Breakthrough Therapy Designation Recently Granted in Patients with NTRK+ Advanced Solid Tumors Who Have Progressed Following Treatment with 1 or 2 Prior TKIs Confirmed Objective Response Rate of 41 Percent in Patients with NTRK+ TKI-Naive Advanced Solid TumorsSAN DIEGO, Oct. 08, 2021 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the presentation of early clinical data from the NTRK-positive TKI-naïve and TKI-pretreated advanced solid tumor cohorts (EXP-5...

PRINCETON, N.J., Oct. 08, 2021 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of 26,666,648 shares of its common stock and warrants to purchase 13,333,324 shares of its common stock at a combined offering price to the public of $0.85 per one share of common stock and one-half of a warrant to purchase one share of common stock. The warrants have an exercise price of $0.85 per share of common stock, are exercisable immediately, and will expire five years from the date of issuance. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Agile Therapeutics, are expected to be approximately $22,666,650. All securities in the offering will be sold by...

Cambridge, MA, Oct. 08, 2021 (GLOBE NEWSWIRE) — Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Kenneth A. Clark, JD, has been appointed to our Board of Directors, effective immediately. Mr. Clark is currently a partner at Wilson Sonsini Goodrich & Rosati (WSGR) based out of the firm’s Palo Alto, CA, office. At WSGR, Ken advises biotech companies in strategic partnerships, mergers and acquisitions, and financing transactions, in addition to a range of other matters. He has previously served as a member of the boards of directors for multiple publicly traded companies, including Pulse BioSciences, Inc. and Pharmacyclics, Inc., in addition to serving two terms on WSGR’s Board of Directors. Ken received his undergraduate degree from Vanderbilt University and earned his juris doctorate from the University of Texas...

BOUCHERVILLE, Quebec, Oct. 08, 2021 (GLOBE NEWSWIRE) — Colabor Group Inc. (TSX: GCL) (“Colabor” or the “Company”) will release its results for the third quarter ended September 4, 2021, after market close on Thursday, October 14, 2021. A conference call to discuss these results will be held on Friday, October 15, 2021 at 9:30 a.m. (Eastern Time). Conference Call: A live broadcast of the conference call will be available on the Company’s website, in the Investors section under Events and presentations. To participate (professional investment community only) or to listen to the live conference call:Date: Friday, October 15, 2021Time: 9:30 a.m. (Eastern Time)   Conference Number: 27568259North-American participants dial toll-free: 1-888-390-0549International and local dial-in: 1-416-764-8682   To listen to...

TAMPA, Fla., Oct. 08, 2021 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (NASDAQ: PCRX) the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that it will host an Investor Day on Friday, October 15, 2021, from 8:00 AM to approximately 12:00 PM ET. Key Opinion Leaders and members of the Pacira executive team will provide updates on the Company’s commercial products and pipeline opportunities. The event is taking place at The Pacira Innovation and Training Center at Tampa (the PITT). In-person attendance requires advance registration and is subject to space limitations.   An agenda as well as a live webcast of the event will be accessible through PaciraInvestorDay.com. An archived replay of the webcast will also become available through the same link following the conclusion...

MCLEAN, Va., Oct. 08, 2021 (GLOBE NEWSWIRE) — Appian (NASDAQ: APPN) today announced that it will release financial results for the third quarter ended September 30, 2021, following the close of market on Thursday, November 4, 2021. The company will host a conference call and live webcast to review its financial results and business outlook. Conference Call Details The conference call will begin at 4:30 p.m. Eastern Time. To access the call, please dial (800) 430-8332 in the U.S. or (323) 289-6581 internationally (Conference ID: 1366306). The call will also be available live via webcast on the Investor Relations page of the Company’s website at http://investors.appian.com. A telephone replay of the conference call can be accessed by dialing (844) 512-2921 in the U.S. or (412) 317-6671 internationally (Access code: 1366306) and will...

Rebranding to HARDHATFREIGHT.com underway to leverage opportunity in rapidly growing construction freight market CHARLOTTE, N.C., Oct. 08, 2021 (GLOBE NEWSWIRE) — LiveToBeHappy, Inc. (OTCM: CAVR, soon to be LTBH) (“LiveToBeHappy” or the “Company”), a land developer and community home builder in the Southern U.S. with a differentiating technology marketing platform, today announced that it has entered into a definitive agreement to add PostBidShip to its technology platform of companies. In addition, the Company intends to re-brand PostBidShip as HARDHATFREIGHT.com, to advance the company’s leadership in the construction freight market. Kevin Vincent Cox, Chief Executive Officer of LiveToBeHappy, Inc., added, “Adding PostBidShip to our portfolio of companies will provide a unique opportunity for us to further streamline the real...

Cyprium Therapeutics, a partner company of Fortress Biotech, is developing CUTX-101 for the treatment of Menkes disease Overall survival significantly improved in patients treated with CUTX-101 Rolling submission of New Drug Application to the FDA for CUTX-101 planned to begin in fourth quarter of 2021; potential to be first FDA-approved treatment for Menkes disease NEW YORK and SOLANA BEACH, Calif., Oct. 08, 2021 (GLOBE NEWSWIRE) — Cyprium Therapeutics, Inc. (“Cyprium”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company, with support from its licensing partner Sentynl Therapeutics, Inc. (“Sentynl”), a wholly owned subsidiary of Cadila Healthcare Limited (“Zydus”), today announced positive results from an efficacy and safety analysis of data integrated from two completed pivotal studies in patients with Menkes...